Arbutus Biopharma Corp (ABUS)

Name: Arbutus Biopharma Corp (ABUS) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001447028 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Arbutus Biopharma Corp reported revenue of $14.08M. Revenue grew 128.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $181.72M.

Key ratios (year ended 2025-12-31)

-271.0%

Operating margin

-237.9%

Net margin

-43.7%

Return on year-end equity

128.2%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-07

Headquarters locality: Burnaby · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$181.72M	$14.08M	$6.17M	$18.14M	$39.02M	$10.99M	$6.91M	$6.01M	$5.95M	$10.70M	$1.49M
R&D Expense	$17.80M	$25.24M	$54.04M	$73.70M	$84.41M	$65.50M	$49.34M	$57.60M	$57.93M	$62.68M	$61.25M
Operating Income	$149.00M	-$38.16M	-$76.32M	-$78.10M	-$65.46M	-$73.52M	-$57.81M	-$143.90M	-$89.78M	-$110.93M	-$491.64M
Net Income	$153.05M	-$33.50M	-$69.92M	-$72.85M	-$69.46M	-$76.25M	-$63.74M	-$153.72M	-$57.06M	-$84.41M	-$384.16M
EPS (Diluted)	n/a	-$0.17	-$0.38	-$0.44	-$0.46	-$0.83	-$1.00	n/a	-$1.21	-$1.56	-$7.24
Total Assets	$274.02M	$94.62M	$131.71M	$144.40M	$195.42M	$204.49M	$137.08M	$105.53M	$227.91M	$237.16M	$275.92M
Total Liabilities	$15.29M	$18.04M	$34.34M	$38.38M	$58.57M	$35.05M	$35.11M	$32.79M	$27.67M	$54.69M	$72.91M
Long-Term Debt	$0	$0	$0	$0	$0	$0	n/a	n/a	n/a	n/a	n/a
Shareholders' Equity	$258.73M	$76.58M	$97.37M	$106.02M	$136.85M	$169.44M	$101.97M	$72.74M	$200.23M	$182.47M	$203.00M
Cash & Equivalents	$19.17M	$18.01M	$36.33M	$26.29M	$30.78M	$109.28M	$52.25M	$31.80M	$36.94M	$54.29M	$23.41M
Operating Cash Flow	-$24.62M	-$39.64M	-$64.85M	-$85.94M	-$35.36M	-$67.53M	-$51.44M	-$71.01M	-$67.87M	-$48.64M	-$57.88M
Capital Expenditures	n/a	$0	$182.0K	$1.01M	$512.0K	$809.0K	$229.0K	$589.0K	$1.14M	$7.26M	$4.00M
Free Cash Flow	n/a	-$39.64M	-$65.03M	-$86.94M	-$35.87M	-$68.34M	-$51.67M	-$71.59M	-$69.00M	-$55.90M	-$61.88M
Shares Outstanding	197.63M	192.53M	189.96M	169.87M	157.46M	144.99M	89.68M	64.78M	55.52M	55.06M	54.84M
Weighted Average Diluted Shares	n/a	191.60M	185.61M	165.96M	150.94M	106.24M	75.84M	n/a	55.30M	54.72M	53.07M
EPS (Basic)	n/a	-$0.17	-$0.38	-$0.44	-$0.46	-$0.83	-$1.00	n/a	-$1.21	-$1.56	-$7.24

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView